Edward J. Ludwig - Chairman of the Board

Former Chairman of the Board, President and Chief Executive Officer of BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company headquartered in Franklin Lakes, New Jersey. Mr. Ludwig joined BD in 1979. He served as CFO from 1995 to 1999. Named President in May 1999 and Chief Executive Officer in January 2000, Mr. Ludwig was elected Chairman in February 2002. He served as Chief Executive Officer through September 2011 and Chairman through June 2012.

Mr. Ludwig served as a member of the Board of Trustees of the College of the Holy Cross (2005-2013) and serves on the Columbia Business School Board of Overseers. He is the Vice Chairman of the Hackensack University Medical Center Network Board of Trustees. Mr. Ludwig is a member of the Board of Directors of Project HOPE, which is dedicated to providing lasting solutions to health crises, with the mission of helping people to help themselves. In the corporate arena, Mr. Ludwig serves as Lead Director on Aetna's Board of Directors and chairs the Board's Finance Committee. He is also a member of the Board of Directors of Xylem, Inc., a leading global water technology provider that launched in 2011 from the spinoff of the water-related businesses of ITT Corporation.

Ari Bronshtein, Director

Mr. Bronshtein has served as CEO of Elron since June 2010 after serving as co-CEO of Elron since May 2009. From March 2006 to April 2009, Mr. Bronshtein served as a director at Elron. In January 2006, Mr. Bronshtein joined Discount Investment Corporation ("DIC") as Vice President. Mr. Bronshtein serves as a director at several of Elron's companies, including RDC, Given Imaging and Starling.

Mr. Bronshtein brings extensive experience in public and private capital raisings, investment management, and business development & analysis. Mr. Bronshtein previously served as Vice President and Head of the Economic and Business Development Division of Bezeq, Israel's national landline operator, prior to which he held various executive positions at Bezeq, Comverse and Tadiran. Currently, Mr. Bronshtein serves as a director at CellCom Israel Ltd. and other companies within the IDB group.

Mr. Bronshtein holds a BA degree in Finance and Management and an MA degree in Finance and Accounting, both from Tel Aviv University.

Zvika Slovin, Ph.D., Director

Dr. Slovin joined Elron in January 2008 as Vice President Medical and Life Sciences, and from May 2009 until June 2010 served as Elron's Co-CEO. Dr. Slovin provides business guidance and serves as a director in several of Elron's group companies, including Kyma, NuLens, BrainsGate and RDC.

Dr. Slovin brings extensive experience in founding and managing successful Israeli start-up companies such as RDC Communications, Gnome, Tactile Technologies and QuantomiX, ultimately leading them to a successful exit.

Dr. Slovin holds a B.Sc in Physics/Atmospheric Sciences, M.Sc in Physics/Atmospheric Sciences (Magna Cum Laude) and Ph.D in Physics from the Hebrew University, Jerusalem and IMT International Campus.

Yaron Elad, Director

Mr. Elad joined Elron in July 2007 as Controller and in January 2010 was appointed as Vice President and Chief Financial Officer. He brings extensive experience in accounting, financing and tax related matters. Prior to joining Elron, Mr. Elad worked at BDO (Isr.), a leading Israeli auditing firm, as manager in the auditing and technical department. In addition, Mr. Elad was a lecturer at Tel Aviv University and other academic institutions, and lectured at the Institute of Certified Public Accountants in Israel and various Israeli government ministries. Mr. Elad serves on the board of directors of RDC, Navitrio and Cloudyn.

Mr. Elad holds a B.A. degree in Economics and Accounting (cum laude) from Tel Aviv University, and an M.Sc. in Finance from Tel Aviv University. He has been a licensed CPA since 2004.

Abraham Ludomirski, M.D, Director

Dr. Ludomirski is the founder of the Vitalife Life Sciences Fund. He is an internationally renowned physician with more than 20 years experience in life sciences, with particular expertise in medical devices, health homecare, and biomaterials. Dr. Ludomirski founded and developed the SafeKeeping Company (remote monitoring of high risk pregnancies), which was later acquired by a leading corporation active in this area. He has been a consultant to a number of Israeli and American venture capital funds and large medical technology companies, including GE Medical, ATL - Philips, Medison, Matria Healthcare, and QED Technologies. He has instructed and has led several start-ups through the process of raising capital, creating strategic partnerships, establishing joint ventures, and successfully achieving regulatory clearances. He currently serves as Director or Chairman of BioControl Medical, Deep Breeze, DIR Technologies, EndoSpan, MST, Recro Pharma, and Sensible Medical Innovations. Previously, Dr. Ludomirski served as Chairman of Sightline Technologies (sold to Stryker) and MediGuide (sold to St. Jude).

Dr. Ludomirski earned his M.D. at the Sackler Tel-Aviv University Medical School and specialized in OB-GYN. Following medical school, he completed his fellowship at the University of Pennsylvania in maternal fetal medicine. He was one of the founders of the fetal surgery program and established an internationally known fetal blood-sampling registry. He served as the Director of the Maternal Fetal Medicine Division and as a Professor of OB-GYN at Temple University Medical School for three years. Dr. Ludomirski has published numerous articles in peer-reviewed journals and has lectured around the world. He has also served as a reviewer for several leading medical journals.

Wayne B. Weisman, Director

Mr. Weisman is a Founder and Managing Partner of SCP Vitalife Partners, and a Partner of SCP Partners, with more than $1 billion under management in a series of venture capital investment funds. He has been a member of the investment committee of Vitalife Life Sciences Fund since its inception, and has worked closely with Vitalife since SCP Partners became Vitalife's U.S. sponsor in 2002. He has extensive experience in venture capital investing, particularly in the life sciences area, dating back to 1990. Mr. Weisman has been a partner of SCP Partners since its inception in 1996. SCP is a multistage private equity manager with $830 million under management in two funds. He has led SCP's efforts in the life sciences area, which include investments in the U.S. and Israel. He has also led several other technology investments for SCP. Mr. Weisman serves as chairman of the board or a director of several portfolio companies. In 1990, Mr. Weisman became vice president and a member of the board of directors of CIP Capital L.P., a Small Business Investment Company licensed by the SBA. Mr. Weisman led many of the successful life science investments made by CIP. From 1987 to 1990, Mr. Weisman operated a management and financial advisory firm focusing on the reorganization and turnaround of troubled companies. He began his career in 1982 practicing reorganization law at a large Philadelphia law firm. Mr. Weisman is a Director or Chairman of several companies, including Argo Medical Technologies, DIR Technologies, EndoSpan, FluidNet, Garnet BioTherapeutics, LZ Therapeutics, Recro Pharma, and Trig Medical.

Mr. Weisman received his B.A. from the University of Pennsylvania, and his J.D. from the University of Michigan Law School. He is the chairman of the board of trustees of Young Scholars School and Young Scholars Frederick Douglass, two inner-city public schools serving approximately 1,000 economically disadvantaged children. He is also a board member of the Philadelphia-Israel Chamber of Commerce and Mid-Atlantic Diamond Ventures, the venture forum of Temple University.

Jonathan Gurfinkel, President and CEO, Director

Mr. Gurfinkel is the co-founder of POCARED Diagnostics™ and brings to the company accumulated management and technical experience in leading high-tech companies.

Mr. Gurfinkel holds a Bachelor and M.Sc. in Electrical Engineering from Ben-Gurion University of the Negev, Beer-Sheba, Israel; and an EMBA from the Hebrew University of Jerusalem.

The P-1000™ is currently under development and not available in the U.S